Summary: Interleukin-2 (IL-2) plays an important role as an immunoregulatory mediator. It is also known to enhance the killing activity of killer cells such as natural killer (NK) cells or lymphokineactivated killer (LAK) cells. When cytotoxic T lymphocytes (CTL) lyse antigen (Ag)-treated target cells, the presence of IL-2 enhances the killing activity of CTL. In the present study, we examined the mechanisms by which IL-2 treated CTL lyse normal target cells at the cellular and mRNA levels. Our results suggest that IL-2 treated CTL can lyse target cells predominantly via Fas-mediated mechanism and to a lesser extent via a granule exocytosis-based mechanism. Interestingly, the level of FasL mRNA in CTL clone remained unchanged following IL-2 treatment, whereas the level of expression of Fas ligand (Fast) on CTL surface was slightly enhanced. On the other hand, treatment with metalloproteinase inhibitor augmented the level of FasL expression on the cell surface of CTL as well as the activity of target cell killing. Our results indicate that IL-2 plays a crucial role in the regulatory mechanisms of target cell killing by CTL without TCR-stimulation.
It is now clear that lysis of target cells by CTL is accomplished mainly through two distinct mechanisms. One involves lysis mediated by granule (containing performn and granzymes) exocytosis [8, 9] , while the other is a Fas-based lysis [10] [11] [12] . While engagement of T cell receptor (TCR) is known to activate both killing mechanisms [11, 13] , the exact intracellular signal transduction pathways for performn or Fas ligand (Fast) expression in CTL remain to be elucidated. A membrane-bound FasL induced after TCR-engagement is known to mediate Fasdependent killing [14, 15] . In contrast, a soluble form of FasL, which is released from CTL surface by metalloproteinases [1 6], inhibits cytotoxicity of the membrane-bound FasL [171.
We previously reported that an influenza virus specific CTL clone (B7B7) can lyse Ag-treated target cells [18] . Recently, Esse et al. [19] reported that CD8+ and CD4+ T cell clones treated with IL-2 lyse normal target cells via a Fas-mediated pathway, although the expression of FasL remained unchanged. In the present study, we examined the pathways through which IL-2 treated CTL lyse normal target cells at cellular and mRNA levels, particularly the mechanisms underlying Fas-mediated killing. Our CTL clone B7B7 at 5 or 6 days after Ag-stimulation was incubated with 100 U/ml of recombinant mouse IL-2 (hereafter termed IL-2: Genzyme, Cambridge, MA) for 3 hrs prior to CTL assay unless otherwise indicated. Preparation of marine DNA probes Murine perform DNA probe was amplified with the RNA PCR Kit (Takara Shuzo Co., Tokyo) using a first-strand cDNA generated from CTL clone B7B7 cellular RNA as a template and two oligonucleotide, 5 '-ACGCATGATCTGCTCTTCG-3 ' (nt; nucleotide 928-946) and 5'-TGGCTACTCTTATGCTGGCC-3' (complementary to nt 1166-1185) [26] . Products corresponding to perform nt 928-1185 were recovered from 1 % SeaKem GTG agarose (FMC BioProducts, Rockland, ME) and directly subcloned into a pGEM-T Vector (Promega Corp., Madison, WI), according to the method recommended by the supplier. The DNA fragment containing nt 928-1185 excised by using Sac II/Spe I double digestion was used as a probe. 
RESULTS

Lysis of target cells by IL-2 treated CTL clone B7B7
In all experiments described in this study, only CTL clone at 5 or 6 days after Ag-stimulation were used, since the CTL clone failed to produce IFN-y or TNF-a (data not shown). CTL clone B7B7 was incubated with P815 or EL-4 cells, both Fas antigenpositive, in the presence of IL-2. As shown in Fig.  1A , the CTL clone lysed both target cells in a dosedependent manner, but failed to lyse target cells in the absence of IL-2. For comparison, a synthetic peptide (residues 518-528 of the HA2 subunit of A/PR/8 virus HA) was added at a concentration of 1 lag/ml to the culture of CTL clone and P815 target cells at the same E/T ratio. CTL clone significantly lysed peptide-treated P815 target cells. The level of peptide-treated target killing was almost similar to that of P815 target killing by IL-2 treated CTL clone.
In the next step, we examined the mechanism of target cell killing by IL-2 treated CTL clone. Figure 1 shows that CTL clone can lyse target cells in the presence of IL-2. It is possible that this lysis is mediated by IL-2-induced enhancement of Fas-antigen expression on target cells. To test such possibility, CTL and target cells were separately preincubated with IL-2 prior to coincubation of both cell types. Figure 2 shows that IL-2 pretreated CTL clone lyoed L1210 F + target cells, but the level of target lysis was lower than that of CTL incubated in the presence of IL-2 (Fig. 1) . In contrast, IL-2 pretreated target cells were not lysed by untreated CTL clone. These results suggest that IL-2 activates CTL for inducing target lysis, but not target cells. We also performed Northern blot analysis to examine FasL and performn mRNA expression on IL-2 treated CTL. CTL clone was stimulated with IL-2 or a combination of phorbol myristate acetate (PMA) and calcium ionophore A23187 (P/A) as a positive control. As shown in Fig. 5, a high Figure 4B shows that lysis of normal target cells by IL-2 treated CTL was to some extent inhibited by EGTA at a concentration of 2 mM, whereas the lysis of Ag-treated target cells by untreated CTL was inhibited by approximately 50% using the same concentration. Considered together, these results indicated that only a limited degree of granule exocytosisbased lysis is involved in target lysis by IL-2 treated CTL. augmentation of FasL expression on the cell surface compared with untreated CTL clone. However, the level of FasL expression was not as high as expected.
In the next set of experiments, CTL clone was treated with IL-2 in the presence of a matrix metalloproteinase (MMP) inhibitor, KB8301, since FasL on the CTL clone is thought to be cleaved from the cell surface by metalloproteinases [16] . The presence of KB8301 enhanced FasL expression on IL-2 treated Metalloproteinases are also known to cleave membrane-bound TNF-a to its soluble form [34] . The release of membrane-bound FasL seems to occur rapidly following activation of T cells and monocytes [16, 35] . As shown in Fig. 7 , untreated CTL clone appeared to express a low level of FasL antigen on the cell surface. However, FasL expression was probably due to background staining. This conclusion is based on our finding that CTL clone treated with normal hamster IgG as first Ab expressed a similar level of FasL as normal CTL clone treated with anti-FasL Ab (data not shown), and that untreated CTL clone failed to kill target cells (Fig. 1) . While the level of FasL expression on CTL surface following IL-2 treatment was only slightly enhanced, our study showed that IL-2 treated CTL produced a strong lysis of target cells. In addition, our results also showed that a protein synthesis inhibitor, cycloheximide, completely blocked the lysis of target cells by IL-2 treated CTL clone (Fig. 6) . These results suggest that newly synthesized protein molecules strongly contribute to target cell killing and that the newly synthesized membrane-bound FasL may be released immediately. Indeed, this notion was supported by our results demonstrating that KB8301, a metalloproteinase inhibitor, enhanced FasL expression on CTL clone and in turn CHX inhibited the enhanced FasL expression induced by KB8301 (Fig.  7) Little is known about cytokines that can directly induce FasL in T lymphocytes. Suda et al. [37] reported that IL-2 could induce FasL mRNA in fresh murine spleen cells. The same study, however, could not confirm that IL-2 directly induces FasL in T lymphocytes, since a heterogeneous population of murine spleen cells were used. Recently, Tsutsui et al. [38] demonstrated that IFN-y inducing factor (IGIF) induced the expression of FasL mRNA in murine NK cell clones. The reason for detection of FasL mRNA following treatment with IL-2 may be due to a low level of basal FasL mRNA expression in NK cell clones. The basal level of FasL mRNA expression in our CTL clone B7B7 seems to be much higher, which might be due to prolonged stimulation of TCR and IL-2.
Liu and colleagues [39] showed that IL-2 stimulates CTL to induce perform and seriee esterase at mRNA level and culture supernatant. It was, however, unclear that these IL-2 induced molecules are also active in lysis of target cells. In our study, enhancement of perform mRNA expression was observed (Fig. 5) , but the activity of BLT esterase in the culture supernatant was hardly detected (Fig.  4A) . Such lack of activity may be due to inhibition of release of perform for yet unknown reasons in spite of the enhancement of perform mRNA. Alternatively, the sensitivity of the BLT esterase assay used in the present study may be very low. As shown in Fig. 4B , EGTA partially inhibited the lysis of target cells by IL-2 treated CTL, indicating involvement of granuleexocytosis mediated killing. However, it is possible that Ca2+ is required for signal transduction of IL-2 cells by membrane-bound FasL [17] . Extrapolation of these findings to our system suggests that treatment with metalloproteinase inhibitors may enhance target lysis by preventing the production of soluble FasL.
leading to FasL expression. Thus, in our experimental system, granule-exocytosis mediated killing may at least in part be involved in target cell lysis.
Other factors may also be involved in IL-2-induced target cell kkilling. These include certain adhesion molecules such as a LFA-l, which may enhance Fas-mediated killing by IL-2 treated CTL. However, IL-2 treatment failed to enhance the expression of LFA-1 antigen on CTL clone and the presence of anti-LFA-1 Ab failed to inhibit lysis of target cells by IL-2 treated CTL (unpublished data). 
